Citadel Advisors
VIR icon

Citadel Advisors’s Vir Biotechnology VIR Stock Holding History

Citadel Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$543K Buy
+53,300
New +$507K ﹤0.01% 9656
2026
Q1 		– Sell
-40,800
Closed -$246K – 14318
2025
Q4 		$246K Buy
40,800
+22,300
+121% +$133K ﹤0.01% 10589
2025
Q3 		$106K Sell
18,500
-2,100
-10% -$10.7K ﹤0.01% 11820
2025
Q2 		$104K Sell
20,600
-8,300
-29% -$44.5K ﹤0.01% 11314
2025
Q1 		$187K Buy
28,900
+7,700
+36% +$68.5K ﹤0.01% 10544
2024
Q4 		$156K Sell
21,200
-10,200
-32% -$80.5K ﹤0.01% 10823
2024
Q3 		$235K Buy
31,400
+10,800
+52% +$93.8K ﹤0.01% 9824
2024
Q2 		$183K Sell
20,600
-7,500
-27% -$71.9K ﹤0.01% 10064
2024
Q1 		$285K Buy
28,100
+6,700
+31% +$68.2K ﹤0.01% 9564
2023
Q4 		$215K Sell
21,400
-17,600
-45% -$161K ﹤0.01% 9811
2023
Q3 		$365K Sell
39,000
-5,500
-12% -$78.4K ﹤0.01% 8742
2023
Q2 		$1.09M Buy
44,500
+12,000
+37% +$301K ﹤0.01% 6283
2023
Q1 		$756K Sell
32,500
-16,700
-34% -$427K ﹤0.01% 7395
2022
Q4 		$1.25M Sell
49,200
-3,400
-6% -$83.3K ﹤0.01% 6390
2022
Q3 		$1.01M Sell
52,600
-5,400
-9% -$137K ﹤0.01% 6965
2022
Q2 		$1.48M Sell
58,000
-96,600
-62% -$2.26M ﹤0.01% 6159
2022
Q1 		$3.98M Sell
154,600
-44,200
-22% -$1.31M ﹤0.01% 4624
2021
Q4 		$8.32M Buy
198,800
+114,300
+135% +$4.48M ﹤0.01% 3366
2021
Q3 		$3.68M Buy
84,500
+13,500
+19% +$584K ﹤0.01% 4921
2021
Q2 		$3.36M Sell
71,000
-3,500
-5% -$159K ﹤0.01% 5331
2021
Q1 		$3.82M Buy
74,500
+14,000
+23% +$755K ﹤0.01% 4878
2020
Q4 		$1.62M Buy
60,500
+37,800
+167% +$1.23M ﹤0.01% 5825
2020
Q3 		$779K Sell
22,700
-7,900
-26% -$340K ﹤0.01% 6488
2020
Q2 		$1.25M Buy
+30,600
New +$1.03M ﹤0.01% 5411

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors's VIR Position: Q2 2026 in Review

Citadel Advisors reduced its Vir Biotechnology (VIR) stake by 53% in Q2 2026, selling an estimated $10.5M and leaving 991,337 shares worth $10.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3561.

Citadel Advisors first reported a position in VIR in Q4 2019 and has held it in 24 quarters since. The position peaked at $34.5M in Q1 2024. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Citadel Advisors held 991,337 shares of Vir Biotechnology worth $10.1M as of Q2 2026.
  • Citadel Advisors sold 1,107,139 Vir Biotechnology shares in Q2 2026, an estimated $10.5M.
  • Vir Biotechnology made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3561 holding.
  • Citadel Advisors first reported a position in Vir Biotechnology in Q4 2019 and has held it in 24 quarters since.
  • Citadel Advisors's Vir Biotechnology position peaked at $34.5M in Q1 2024.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.